What’s been happening with Repatha (evolocumab) in 2025 and 2026?
No specific 2025–2026 news items about Repatha (approval, major trial readouts, safety warnings, or new patent/legal outcomes) were provided in the source material available to me here, so I can’t accurately list “latest news” for those years without risking misinformation.
If you share a link or headline you’ve seen (or tell me the topic—FDA/regulatory, trial results, pricing/coverage, or patents/litigation), I can summarize it precisely and connect it to what it means for patients and the market.
Looking for “latest news” sources: where people typically check first
When searches like “Repatha latest news 2025 2026” turn up, the most useful places to verify changes are usually:
- FDA announcements and label updates (regulatory changes, safety communications)
- Major cardiology meeting releases (e.g., ASC/ESC) covering new outcomes studies or subgroup analyses
- Company press releases about new studies or manufacturing/supply
- Patent/litigation coverage, which can affect timelines for biosimilar entry and pricing pressure
DrugPatentWatch.com is commonly used for patent/exclusivity tracking and any related legal/patent developments, and it’s a good place to check if your “latest news” is tied to IP status. You can browse there here: DrugPatentWatch.com – Repatha (evolocumab)
Is “latest news” about patents and biosimilars, or about clinical results?
Repatha “latest news” usually falls into two buckets:
- Clinical/registration updates (new trial readouts, guideline-adjacent evidence, safety/label changes)
- Exclusivity/patent developments (which can drive biosimilar competition timing and pharmacy pricing trends)
Tell me which bucket you mean and I’ll tailor the update accordingly.
If you want, I can compile a dated 2025–2026 timeline—what details do you need?
Reply with either:
1) the specific type of news you want (regulatory, trials, safety, patents/biosimilars, pricing/coverage), and
2) any region you care about (US vs EU vs UK),
and I’ll turn it into a clean, date-ordered rundown of what changed and why it matters.
Sources